On Monday, Pfizer society declared that it was starting a pilot program for COVID-19 immunization in four US states to improve its vaccine candidate’s delivery and deployment plan.
The US drugmaker announced it had chosen Rhode Island, Texas, New Mexico, and Tennessee for the program since their differences in overall size, diversity of populations, immunization infrastructure, and the states’ need to arrive to individuals in different urban and rural environments.
In a statement, Pfizer said: The four states included in this pilot program will not receive vaccine doses earlier than other states by virtue of this pilot, nor will they receive any differential consideration.
It should be noted that last Monday, Pfizer published initial data about its vaccine that is developed with German partner BioNTech SE and showed an efficacy of more than 90 percent effective.
Moreover, rival Moderna Inc declared that its experimental vaccine was 94.5 percent efficient in preventing COVID-19 based on interim data from a late-stage trial, which increasing hopes that these vaccines might be ready for use soon.
The two vaccines of Pfizer and Moderna use a new technology named synthetic messenger RNA to activate the immune system against the virus. Otherwise, experts expressed their concerns about the distribution challenges related with Pfizer’s vaccine due to its specialized storage conditions.